Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Combined Modality Therapy
  • Head and Neck Neoplasms
  • Maximum Tolerated Dose

abstract

  • Although high response and complete resection rates were again demonstrated, results with the MVP400 regimen were not improved over those achieved with MVP regimen tested earlier with Stage IIIA (N2) patients. The authors continue to recommend MVP as an induction chemotherapy regimen for clinical trials.

publication date

  • October 1999

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19991001)86:7<1189::AID-CNCR13>3.0.CO;2-N

PubMed ID

  • 10506703

Additional Document Info

start page

  • 1189

end page

  • 97

volume

  • 86

number

  • 7